Cargando…
Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis
BACKGROUND: No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing–remitting multiple sclerosis (RRMS). OBJECTIVE: To asse...
Autores principales: | Arnold, Douglas L., Shang, Shulian, Dong, Qunming, Meergans, Matthias, Naylor, Maria L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113732/ https://www.ncbi.nlm.nih.gov/pubmed/30181780 http://dx.doi.org/10.1177/1756286418795085 |
Ejemplares similares
-
Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
por: Newsome, Scott D., et al.
Publicado: (2016) -
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
por: Newsome, Scott D., et al.
Publicado: (2018) -
Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
por: Hendin, Barry, et al.
Publicado: (2018) -
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
por: Arnold, Douglas L, et al.
Publicado: (2014) -
Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis
por: Scott, Thomas F, et al.
Publicado: (2016)